Our tests provide valuable insights into clinically relevant alterations in DNA that drive cancer growth, help transform targeted therapy, immunotherapy, and chemotherapy clinical trials into viable cancer treatment options.
Each cancer is unique and each tumor can vary at the molecular level.
Novogene’s next-generation sequencing-based assay detects genomic alterations relevant for the diagnosis and treatment of solid tumors according to clinical guidelines and medical literature. This NGS assay includes cancer immunotherapy biomarkers, such as Tumor Mutational Burden (TMB), Blood Tumor Mutational Burden (bTMB), Microsatellite Instability (MSI) and four forms of genomic alterations: Single Nucleotide Variant (SNV), Insertion/Deletion (InDel), Copy Number Variation (CNV), and Fusion. Our reports present the mutations detected in the submitted patient sample and information regarding approved therapies, clinical trials and other scientific findings.
Precision Medicine is an emerging approach to disease prevention and treatment that takes into account the variation in genetics, environment, and lifestyle between individuals.
Precision Medicine is a novel approach to cancer treatment. The Comprehensive Genomic Profiling (CGP) test can help patients pinpoint mutated genes and enables Novogene to provide interpretation of alterations as well as any corresponding therapy instructions. Ideally, upon implementation of the suggested therapies, patient condition will improve in a short time span and unnecessary side effects will be avoided, since the medical treatment is specifically tailored to the genetics of the patient.
Genetic testing can give you and your doctor more information about your cancer. This information can help your doctor determine the most appropriate treatment strategy. Since cancer treatment is often complicated by the type of cancer, the physical condition of the patient, and the patient’s medication history, Novogene recommends discussing suitable testing products and timing with your physician, so as to enhance testing effectiveness.
Novogene's clinical oncology testing performs multi-gene testing for cancer patients. This testing service is different from the single-gene testing program available in hospitals, as it can provide complete genetic alteration analysis on genes included in the testing panel.
We provide information pertaining to genetic mutations in addition to related interpretation, medication information, clinical trials information and related references.
Information about identified genomic alterations of all types and interpretation of results.
Early detection provides the opportunity to maximize health outcomes for your high-risk patient groups with patient-tailored screening programs, preventive measeures and proactive treatment.
The field is required.